SG81261A1 - Method for treating heart failure - Google Patents

Method for treating heart failure

Info

Publication number
SG81261A1
SG81261A1 SG9900526A SG1999000526A SG81261A1 SG 81261 A1 SG81261 A1 SG 81261A1 SG 9900526 A SG9900526 A SG 9900526A SG 1999000526 A SG1999000526 A SG 1999000526A SG 81261 A1 SG81261 A1 SG 81261A1
Authority
SG
Singapore
Prior art keywords
heart failure
treating heart
treating
failure
heart
Prior art date
Application number
SG9900526A
Other languages
English (en)
Inventor
Liang Chen Yuhpyng
Andrea Fossa Anthony
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SG81261A1 publication Critical patent/SG81261A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG9900526A 1998-02-17 1999-02-10 Method for treating heart failure SG81261A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7493498P 1998-02-17 1998-02-17

Publications (1)

Publication Number Publication Date
SG81261A1 true SG81261A1 (en) 2001-06-19

Family

ID=22122537

Family Applications (1)

Application Number Title Priority Date Filing Date
SG9900526A SG81261A1 (en) 1998-02-17 1999-02-10 Method for treating heart failure

Country Status (28)

Country Link
US (1) US6043260A (pt)
EP (1) EP0951906A1 (pt)
JP (1) JPH11292766A (pt)
KR (1) KR19990072616A (pt)
CN (1) CN1231176A (pt)
AP (1) AP9901464A0 (pt)
AR (1) AR017723A1 (pt)
AU (1) AU1732999A (pt)
BG (1) BG103180A (pt)
BR (1) BR9900653A (pt)
CA (1) CA2262252C (pt)
EA (1) EA199900124A3 (pt)
GT (1) GT199900015A (pt)
HR (1) HRP990054A2 (pt)
HU (1) HUP9900386A3 (pt)
ID (1) ID23218A (pt)
IL (1) IL128531A0 (pt)
IS (1) IS4975A (pt)
MA (1) MA26608A1 (pt)
NO (1) NO990722L (pt)
OA (1) OA10976A (pt)
PA (1) PA8467401A1 (pt)
PE (1) PE20000266A1 (pt)
PL (1) PL331507A1 (pt)
SG (1) SG81261A1 (pt)
TN (1) TNSN99024A1 (pt)
TR (1) TR199900328A2 (pt)
ZA (1) ZA991220B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US6387894B1 (en) * 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
WO2001021259A2 (en) * 1999-09-21 2001-03-29 Emory University Use and compositions for treating platelet-related disorders using anagrelide
PL357589A1 (en) * 2000-01-18 2004-07-26 Pfizer Products Inc. Corticotropin releasing factor antagonists
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
MXPA04007026A (es) 2002-02-22 2004-10-11 Pharmacia & Up John Company Pirimidinonas y pirimidintionas sustituidas.
BR0308391A (pt) * 2002-03-13 2005-01-11 Pharmacia & Upjohn Co Llc Derivados de pirazolo(1,5-a)piridina como moduladores neurotransmissores
US6964965B2 (en) * 2002-04-26 2005-11-15 Pharmacia & Upjohn Substituted pyrazine derivatives
MXPA05002418A (es) * 2002-09-12 2005-05-27 Pharmacia & Upjohn Co Llc Derivados de 1,4-pirazina sustituidos.
AR041470A1 (es) * 2002-10-17 2005-05-18 Upjohn Co Compuestos de pirrolo (1,2 - b) piridazina y sus usos
WO2004046136A1 (en) * 2002-11-21 2004-06-03 Pharmacia & Upjohn Company Llc Pyrazine compounds as crf modulators
JP2006524223A (ja) * 2003-04-23 2006-10-26 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Ｃｒｆアンタゴニストとしての置換されたピリミジノンおよびピリミジンチオン
EP1622911A2 (en) * 2003-05-07 2006-02-08 Pharmacia & Upjohn Company LLC Pyrrolo[1,2-b]pyridazine compounds and their use as crf-1 receptor antagonists
MXPA05012082A (es) * 2003-05-09 2006-02-22 Pharmacia & Upjohn Co Llc Compuestos como antagonistas del receptor crf1.
EP1625115A1 (en) * 2003-05-09 2006-02-15 Pharmacia & Upjohn Company LLC Substituted pyrimidine derivatives
JP2006525989A (ja) * 2003-05-09 2006-11-16 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Ｃｎｓ障害を治療するためのｃｒｆ１受容体アンタゴニストとしてのピラジノン
US20050209289A1 (en) * 2004-03-16 2005-09-22 Talarico Matthew T Method for vascular dysregulation
US20060211710A1 (en) * 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
US8338441B2 (en) * 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033750A1 (en) * 1994-06-08 1995-12-14 Pfizer Inc. Corticotropin releasing factor antagonists
EP0773023A1 (en) * 1995-11-08 1997-05-14 Pfizer Inc. New uses for corticotropin releasing factor (CRF) antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033750A1 (en) * 1994-06-08 1995-12-14 Pfizer Inc. Corticotropin releasing factor antagonists
EP0773023A1 (en) * 1995-11-08 1997-05-14 Pfizer Inc. New uses for corticotropin releasing factor (CRF) antagonists

Also Published As

Publication number Publication date
ZA991220B (en) 2000-08-16
GT199900015A (es) 2000-07-26
CA2262252C (en) 2006-01-10
PE20000266A1 (es) 2000-04-07
NO990722L (no) 1999-08-18
TNSN99024A1 (fr) 2005-11-10
CA2262252A1 (en) 1999-08-17
AR017723A1 (es) 2001-09-12
KR19990072616A (ko) 1999-09-27
HUP9900386A3 (en) 1999-12-28
CN1231176A (zh) 1999-10-13
IL128531A0 (en) 2000-01-31
OA10976A (en) 2001-11-05
ID23218A (id) 2000-03-30
EA199900124A3 (ru) 1999-12-29
BG103180A (bg) 1999-09-30
HUP9900386A2 (hu) 1999-11-29
EP0951906A1 (en) 1999-10-27
HRP990054A2 (en) 2000-02-29
AP9901464A0 (en) 1999-03-31
AU1732999A (en) 1999-09-02
MA26608A1 (fr) 2004-12-20
NO990722D0 (no) 1999-02-16
BR9900653A (pt) 2000-10-17
TR199900328A2 (xx) 1999-10-21
EA199900124A2 (ru) 1999-08-26
US6043260A (en) 2000-03-28
IS4975A (is) 1999-08-18
PA8467401A1 (es) 2000-09-29
HU9900386D0 (en) 1999-04-28
JPH11292766A (ja) 1999-10-26
PL331507A1 (en) 1999-08-30

Similar Documents

Publication Publication Date Title
SG81261A1 (en) Method for treating heart failure
EP1180040A4 (en) METHODS OF TREATING CONGESTIVE HEART FAILURE
EP0792371A4 (en) COMBINED ACNE TREATMENT PROCESS
SG50018A1 (en) Method for developing treatment
HK1010220A1 (en) Method for surface treatment.
GB2359314B (en) Technique for treating wells
GB9605828D0 (en) Treatment method
IL130531A0 (en) Method for treating glaucoma
EP1009403A4 (en) METHOD FOR TREATING SCHIZOPHRENIA
PL341667A1 (en) Method of treating cooped
IL125762A0 (en) Method for treating heart failure
GB9714841D0 (en) Treatment method
EP0786999A4 (en) COMBINED ACNE TREATMENT PROCESS
ZA974978B (en) Formulation and method for treating congestive heart failure
ZA975264B (en) Method for treating congestive heart failure.
ZA200007396B (en) Method of treatment.
HU9903735D0 (en) Method for treating congestive heart failure
ZA988745B (en) Compounds for treating heart failure
EA199900063A3 (ru) Способ лечения организма пациента
GB9703102D0 (en) Treatment method
GB9822681D0 (en) Method of treatment
GB9614741D0 (en) Treatment method
GB9614742D0 (en) Treatment method
GB9600610D0 (en) Treatment method
GB9614743D0 (en) Treatment method